- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Depression
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 614KB)
Esketamine – July 2022
Esketamine: Nasal spray solution 28 mg in 0.2 mL; Spravato®
Last updated
28 October 2022